Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-10-22
DOI
10.1016/j.annonc.2023.10.122
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: Exploratory analysis of the SERENA-2 phase 2 trial.
- (2023) Mafalda Oliveira et al. JOURNAL OF CLINICAL ONCOLOGY
- AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
- (2023) Sara M. Tolaney et al. JOURNAL OF CLINICAL ONCOLOGY
- Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
- (2023) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves
- (2022) Joseph J. Zhao et al. BMC Medical Research Methodology
- Abstract OT2-11-05: SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable ESR1m who have not experienced disease progression on first-line therapy
- (2022) François-Clément Bidard et al. CANCER RESEARCH
- Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
- (2022) Miguel Martín et al. EUROPEAN JOURNAL OF CANCER
- Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
- (2022) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
- (2022) Francois-Clement Bidard et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA20 Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors
- (2022) M.P. Goetz et al. ANNALS OF ONCOLOGY
- 211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study
- (2022) M. Martin Jimenez et al. ANNALS OF ONCOLOGY
- Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
- (2022) François-Clément Bidard et al. LANCET ONCOLOGY
- Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma
- (2022) Dominic Wei Ting Yap et al. JAMA Oncology
- Detection of ESR1 Mutations Based on Liquid Biopsy in Estrogen Receptor-Positive Metastatic Breast Cancer: Clinical Impacts and Prospects
- (2021) Hao Liao et al. Frontiers in Oncology
- IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves
- (2021) Na Liu et al. BMC Medical Research Methodology
- Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma
- (2021) Joseph J. Zhao et al. JOURNAL OF CLINICAL ONCOLOGY
- ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor positive breast cancer: A combined analysis of the phase III SoFEA and EFECT trials
- (2020) Nicholas C. Turner et al. CLINICAL CANCER RESEARCH
- Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL
- (2020) M. Martin et al. ANNALS OF ONCOLOGY
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- ESR1 mutations in breast cancer
- (2019) Derek Dustin et al. CANCER
- Early enrichment of ESR1 mutations and the impact on gene expression in pre-surgical primary breast cancer treated with aromatase inhibitors
- (2019) Mariana F Leal et al. CLINICAL CANCER RESEARCH
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
- The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials
- (2019) Omar Najim et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
- (2019) Dennis J. Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
- (2018) Takashi Takeshita et al. Molecular Cancer
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA damage repair defects as a new class of endocrine treatment resistance driver
- (2018) Meenakshi Anurag et al. Oncotarget
- PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
- (2016) Charlotte Fribbens et al. JOURNAL OF CLINICAL ONCOLOGY
- ActivatingESR1Mutations Differentially Affect the Efficacy of ER Antagonists
- (2016) Weiyi Toy et al. Cancer Discovery
- Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data
- (2015) Lesley A. Stewart et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
- (2013) Stephen RD Johnston et al. LANCET ONCOLOGY
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
- Clonal evolution in cancer
- (2012) Mel Greaves et al. NATURE
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
- (2010) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started